Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature

The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-ca...

Full description

Bibliographic Details
Main Authors: Hideki Furuya, Ian Pagano, Keanu Chee, Takashi Kobayashi, Regan S. Wong, Riko Lee, Charles J. Rosser
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/9/4/166
id doaj-083b2390ca2c43aa95061a6a383f9d8d
record_format Article
spelling doaj-083b2390ca2c43aa95061a6a383f9d8d2020-11-25T01:33:52ZengMDPI AGDiagnostics2075-44182019-10-019416610.3390/diagnostics9040166diagnostics9040166Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic SignatureHideki Furuya0Ian Pagano1Keanu Chee2Takashi Kobayashi3Regan S. Wong4Riko Lee5Charles J. Rosser6Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USACancer Prevention in the Pacific Program University of Hawaii Cancer Center, Honolulu, HI 96813, USATranslational and Clinical Research Program University of Hawaii Cancer Center, Honolulu, HI 96813, USADepartment of Urology, Kyoto University, Kyoto 606-8507, JapanDivision of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USATranslational and Clinical Research Program University of Hawaii Cancer Center, Honolulu, HI 96813, USADivision of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USAThe ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E—APOE; angiogenin—ANG; carbonic anhydrase 9—CA9; interleukin 8—IL-8; matrix metalloproteinase 9—MMP-9; matrix metalloproteinase 10—MMP10; plasminogen activator inhibitor 1—PAI-1; syndecan—SDC1; and vascular endothelial growth factor—VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.https://www.mdpi.com/2075-4418/9/4/166biomarkersbladder cancermultiplexproteinurine
collection DOAJ
language English
format Article
sources DOAJ
author Hideki Furuya
Ian Pagano
Keanu Chee
Takashi Kobayashi
Regan S. Wong
Riko Lee
Charles J. Rosser
spellingShingle Hideki Furuya
Ian Pagano
Keanu Chee
Takashi Kobayashi
Regan S. Wong
Riko Lee
Charles J. Rosser
Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
Diagnostics
biomarkers
bladder cancer
multiplex
protein
urine
author_facet Hideki Furuya
Ian Pagano
Keanu Chee
Takashi Kobayashi
Regan S. Wong
Riko Lee
Charles J. Rosser
author_sort Hideki Furuya
title Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
title_short Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
title_full Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
title_fullStr Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
title_full_unstemmed Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature
title_sort comparison of commercial elisa kits, a prototype multiplex electrochemoluminescent assay, and a multiplex bead-based immunoassay for detecting a urine-based bladder-cancer-associated diagnostic signature
publisher MDPI AG
series Diagnostics
issn 2075-4418
publishDate 2019-10-01
description The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E—APOE; angiogenin—ANG; carbonic anhydrase 9—CA9; interleukin 8—IL-8; matrix metalloproteinase 9—MMP-9; matrix metalloproteinase 10—MMP10; plasminogen activator inhibitor 1—PAI-1; syndecan—SDC1; and vascular endothelial growth factor—VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.
topic biomarkers
bladder cancer
multiplex
protein
urine
url https://www.mdpi.com/2075-4418/9/4/166
work_keys_str_mv AT hidekifuruya comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature
AT ianpagano comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature
AT keanuchee comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature
AT takashikobayashi comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature
AT reganswong comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature
AT rikolee comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature
AT charlesjrosser comparisonofcommercialelisakitsaprototypemultiplexelectrochemoluminescentassayandamultiplexbeadbasedimmunoassayfordetectingaurinebasedbladdercancerassociateddiagnosticsignature
_version_ 1725075298623422464